<DOC>
	<DOCNO>NCT01488994</DOCNO>
	<brief_summary>The purpose study assess BAX 326 pharmacokinetic parameter , evaluate hemostatic efficacy , safety , immunogenicity , change health-related quality life pediatric patient .</brief_summary>
	<brief_title>BAX 326 Pediatric Study</brief_title>
	<detailed_description>The secondary outcome measure : Area Under Plasma Concentration Versus Time Curve From 0 72 Hours ( h ) Post-infusion analysis do due different time-points last PK blood sample , AUC0-72 h redundant total AUC include PK analysis .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Main Participant and/or legal representative has/have voluntarily provide sign informed consent Participant severe ( FIX level &lt; 1 % ) moderately severe ( FIX level ≤ 2 % ) hemophilia B Participant &lt; 12 year old time screen Participant evidence history FIX inhibitor ( base participant 's medical record ) Participant immunocompetent evidence CD4 count ≥ 200 cells/mm^3 Main Participant detectable FIX inhibitor screening , titer ≥ 0.6 Bethesda Unit ( BU ) Participant history allergic reaction , e.g . anaphylaxis , follow exposure FIX concentrate ( ) Participant evidence ongoing recent thrombotic disease Participant inherit acquire hemostatic defect hemophilia B</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>